Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydralazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.96 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.96 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.57 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.57 |
| ▸ | EGFR known ✓ | P00533 | 7/20 | 0.57 |
| ▸ | KDR known ✓ | P35968 | 7/20 | 0.57 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.50 |
| ▸ | GOT1 | P17174 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | NPC1 | O15118 | 3/20 | 0.96 |
| ▸ | RAB9A | P51151 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydralazine SCHEMBL27864907 | 1.00 | GOT1 (1.00) | GOT1MAPTTDP1KDM4ETP53 | |
| Hydralazine SCHEMBL36271 | 1.00 | GOT1 (1.00) | GOT1MAPTTDP1KDM4ETP53 | |
| Hydralazine SCHEMBL7810 | 0.98 | ALDH1A1 (1.00) | GOT1MAPTTDP1KDM4ETP53 | |
| Hydralazine SCHEMBL3995896 | 0.98 | ALDH1A1 (1.00) | GOT1MAPTTDP1KDM4ETP53 | |
| Hydralazine SCHEMBL1650561 | 0.94 | ALDH1A1 (0.93) | GOT1MAPTTDP1KDM4ETP53 | |
| Dihydralazine SCHEMBL13724517 | 0.94 | ALDH1A1 (0.93) | GOT1MAPTTDP1KDM4ETP53 | |
| Hydralazine SCHEMBL2780318 | 0.93 | ALDH1A1 (0.89) | GOT1MAPTTDP1KDM4ETP53 | |
| Hydralazine SCHEMBL2781885 | 0.88 | NPC1 (0.81) | GOT1MAPTTDP1KDM4ETP53 | |
| Hydralazine SCHEMBL8703662 | 0.88 | ALDH1A1 (0.81) | GOT1MAPTTDP1KDM4ETP53 | |
| Hydralazine SCHEMBL2779460 | 0.88 | NPC1 (0.81) | GOT1MAPTTDP1KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256161-A9 | Methods and Compositions for Treating a Disease Condition in a Subject | Palo Alto Investors LP | 2023-08-17 | — | — | US | disclosed |
| US-11382513-B2 | Methods and compositions for treating a condition in a subject | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210121625-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | YUN ANTHONY JOONKYOO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200360271-A1 | Methods and Compositions for Treating a Renal Disease Condition in a Subject | Palo Alto Investors LP | 2020-11-19 | — | — | US | disclosed |
| US-10716749-B2 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS (US) | 2020-07-21 | — | — | US | disclosed |
| CN-109475645-A | MicroRNA composition and its preparation and application | 先进瑞金医疗技术有限公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20180125419-A1 | Methods and Compositions for Treating a Condition in a Subject | PALO ALTO INVESTORS | 2018-05-10 | — | — | US | disclosed |
| US-9833618-B2 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS (US) | 2017-12-05 | — | — | US | disclosed |
| US-20140350041-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | PALO ALTO INVESTORS | 2014-11-27 | — | — | US | disclosed |
| US-8788041-B2 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110029030-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | PALO ALTO INVESTORS | 2011-02-03 | — | — | US | disclosed |
| US-20070112327-A1 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS | 2007-05-17 | — | — | US | disclosed |
| US-20060206149-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-09-14 | — | — | US | disclosed |
| US-20060116721-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-06-01 | — | — | US | disclosed |
| WO-2006044694-A2 | METHODS AND COMPOSITIONS FOR TREATING A DISEASE CONDITION IN A SUBJECT | PALO ALTO INVESTORS (US) | 2006-04-27 | — | — | WO | disclosed |